Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication


Por: Rondon-Lorefice, I, Lopez, JI, Ugalde-Olano, A, Zufiaurre, M, Astobiza, I, Martin-Martin, N, Bozal-Basterra, L, Garcia-Longarte, S, Zabala-Letona, A, Rey, S, Santos-Martin, A, Unda, M, Loizaga-Iriarte, A, Graupera, M, Nuciforo, P, Carracedo, A and Mendizabal, I

Publicada: 1 jun 2026 Ahead of Print: 1 nov 2025
Resumen:
Among the extensive genomic alterations in prostate cancer, phosphatase and tensin homolog (PTEN) deletion stands out as one of the most consistently observed events. PTEN loss in prostate tumors is primarily associated with cancer-cell proliferation and survival through the activation of the phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT)-mechanistic target of rapamycin (mTOR) (PI3K-AKT-mTOR) signaling pathway. However, the use of PTEN as a robust biomarker in clinical practice is hampered by its complex epigenetic, transcriptional and post-translational regulation. In situ protein assessment by immunohistochemistry (IHC) captures PTEN protein status, but it does not report on associated tumor microenvironment remodeling. Here, we undertook an approach that combined PTEN immunoreactivity analysis with high-throughput transcriptional analysis to gain insights into the downstream functional effects of PTEN protein loss in primary tumors. Our extensive bioinformatic analyses highlighted stromal remodeling as a prominent cancer cell-extrinsic process associated with PTEN loss. By extending our transcriptomic computational strategy to Pten loss-driven murine prostate cancer, we validated the causal role of Pten in the stromal reaction observed in clinical specimens. Mechanistically, we provide experimental evidence for the activation of a paracrine program that encompasses enhanced transforming growth factor beta (TGF-beta) signaling and that is compatible with the secretome of PTEN-deficient senescent cancer cells. Finally, our findings enable the sub-stratification of tumors with PTEN loss based on their senescence-associated stroma remodeling program to distinguish indolent from aggressive cases. Our study provides relevant biological context to the cellular and molecular alterations unleashed upon PTEN protein loss in prostate cancer.

Filiaciones:
Rondon-Lorefice, I:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

Lopez, JI:
 Biocruces Bizkaia Hlth Res Inst, Leioa, Spain

Ugalde-Olano, A:
 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Basurto Univ Hosp, Dept Pathol, Bilbao, Spain

 Biocruces Bizkaia Hlth Res Inst, Traslat Prostate Canc Res Lab, CIC bioGUNE Basurto, Bilbao, Spain

Zufiaurre, M:
 Basurto Univ Hosp, Dept Pathol, Bilbao, Spain

Astobiza, I:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Martin-Martin, N:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Bozal-Basterra, L:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Garcia-Longarte, S:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Zabala-Letona, A:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Rey, S:
 Basurto Univ Hosp, Dept Urol, Bilbao, Spain

Santos-Martin, A:
 Biocruces Bizkaia Hlth Res Inst, Leioa, Spain

 Basurto Univ Hosp, Dept Urol, Bilbao, Spain

Unda, M:
 Biocruces Bizkaia Hlth Res Inst, Leioa, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Biocruces Bizkaia Hlth Res Inst, Traslat Prostate Canc Res Lab, CIC bioGUNE Basurto, Bilbao, Spain

 Basurto Univ Hosp, Dept Urol, Bilbao, Spain

Loizaga-Iriarte, A:
 Biocruces Bizkaia Hlth Res Inst, Leioa, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Biocruces Bizkaia Hlth Res Inst, Traslat Prostate Canc Res Lab, CIC bioGUNE Basurto, Bilbao, Spain

 Basurto Univ Hosp, Dept Urol, Bilbao, Spain

:
 Josep Carreras Leukemia Res Inst IJC, Endothelial Pathobiol & Microenvironm Grp, Barcelona, Spain

 ICREA, Barcelona, Spain

Nuciforo, P:
 Vall dHebron Inst Oncol VHIO, Mol Oncol Grp, Barcelona, Spain

Carracedo, A:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Biocruces Bizkaia Hlth Res Inst, Traslat Prostate Canc Res Lab, CIC bioGUNE Basurto, Bilbao, Spain

 Basque Fdn Sci, IKERBASQUE, Bilbao, Spain

 Univ Basque Country UPV EHU, Biochem & Mol Biol Dept, Bilbao, Spain

Mendizabal, I:
 Basque Res & Technol Alliance BRTA, Ctr Cooperat Res Biosci CIC bioGUNE, Derio, Spain

 Biocruces Bizkaia Hlth Res Inst, Traslat Prostate Canc Res Lab, CIC bioGUNE Basurto, Bilbao, Spain

 Basque Fdn Sci, IKERBASQUE, Bilbao, Spain
ISSN: 15747891





Molecular Oncology
Editorial
John Wiley and Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Países Bajos
Tipo de documento: Article
Volumen: 20 Número: 6
Páginas: 1429-1452
WOS Id: 001615456000001
ID de PubMed: 41247227
imagen Green Submitted, gold

MÉTRICAS